Search Result

Results for "

hepatic injury

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (4) Antibiotic (1) Apoptosis (9) Atg8/LC3 (1) Autophagy (3) Bacterial (1) Bcl-2 Family (1) c-Met/HGFR (1) Caspase (2) COX (3) Drug Derivative (1) Endogenous Metabolite (2) ERK (5) Factor Xa (1) Ferroptosis (1) FXR (2) Glycosidase (1) Histamine Receptor (2) Histone Acetyltransferase (1) HIV (1) Interleukin Related (1) IRE1 (1) Isotope-Labeled Compounds (2) JNK (3) Lipoxygenase (2) NF-κB (7) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (2) p62 (1) Parasite (1) Phosphodiesterase (PDE) (2) Reactive Oxygen Species (ROS) (2) Reference Standards (5) TGF-beta/Smad (3) Thrombin (1) Toll-like Receptor (TLR) (2) γ-Glutamyl Transferase (GGT) (2)
By Research Areas:	Cancer (9) Cardiovascular Disease (11) Infection (2) Inflammation/Immunology (15) Metabolic Disease (7) Neurological Disease (5)

By Targets:

Akt (1)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (4)

Antibiotic (1)

Apoptosis (9)

Atg8/LC3 (1)

Autophagy (3)

Bacterial (1)

Bcl-2 Family (1)

c-Met/HGFR (1)

Caspase (2)

COX (3)

Drug Derivative (1)

Endogenous Metabolite (2)

ERK (5)

Factor Xa (1)

Ferroptosis (1)

FXR (2)

Glycosidase (1)

Histamine Receptor (2)

Histone Acetyltransferase (1)

HIV (1)

Interleukin Related (1)

IRE1 (1)

Isotope-Labeled Compounds (2)

JNK (3)

Lipoxygenase (2)

NF-κB (7)

NO Synthase (1)

Nuclear Hormone Receptor 4A/NR4A (2)

p62 (1)

Parasite (1)

Phosphodiesterase (PDE) (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (5)

TGF-beta/Smad (3)

Thrombin (1)

Toll-like Receptor (TLR) (2)

γ-Glutamyl Transferase (GGT) (2)

By Research Areas:

Cancer (9)

Cardiovascular Disease (11)

Infection (2)

Inflammation/Immunology (15)

Metabolic Disease (7)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10102

Kp7-6 2 Publications Verification	Apoptosis	Metabolic Disease Cancer
Kp7-6, a Fas mimetic peptide, is a Fas/FasL antagonist. Kp7-6 protects cells from Fas-mediated apoptosis, and protects mice from Fas-mediated hepatic injury .

HY-N2109

Macranthoidin A	Others	Metabolic Disease
Macranthoidin A is an orally active saponin from Flos Lonicerae. Macranthoidin A possess protection effects on hepatic injury caused by Acetaminophen, Cd, and CCl4, and conspicuous depressant effects on swelling of ear croton oil .

HY-15383

Glyparamide	Others	Others
Glyparamide is an orally active chlorophenyl-containing sulfonylurea. Glyparamide shows hypoglycemic activity and rarely causes hepatic injury .

HY-42682

D(+)-Galactosamine hydrochloride 2 Publications Verification D-Galactosamine HCl	Drug Derivative	Inflammation/Immunology
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-P2149

Concanavalin A 5 Publications Verification	Antibiotic Apoptosis	Infection Inflammation/Immunology Cancer
Concanavalin A is a Ca ²⁺/Mn ²⁺-dependent and mannose/glucose-binding plant lectin that can be found in jack bean. Concanavalin A can induce programmed cell death. Concanavalin A can be used to induce acute hepatic injury .

HY-N7905

Myricetin 3'-glucoside	Others	Inflammation/Immunology
Myricetin 3'-glucoside is a glycoside derivative of quercetin. Myricetin 3'-glucoside significantly prevents ethanol-induced hepatotoxicity by reducing hepatic transaminase activity and inflammatory response in HepG2 cells. Myricetin 3'-glucoside has a certain protective effect on alcohol-induced liver injury .

HY-17464

Cilostazol 5 Publications Verification OPC 13013	Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-N2109R

Macranthoidin A (Standard)	Reference Standards Others	Metabolic Disease
Macranthoidin A (Standard) is the analytical standard of Macranthoidin A. This product is intended for research and analytical applications. Macranthoidin A is an orally active saponin from Flos Lonicerae. Macranthoidin A possess protection effects on hepatic injury caused by Acetaminophen, Cd, and CCl4, and conspicuous depressant effects on swelling of ear croton oil .

HY-W027126

Hepatoprotective agent-2	Apoptosis	Metabolic Disease
Hepatoprotective agent-2 (compound 2a), a 4-phenyl-tetrahydroquinoline derivative, displays a remarkable hepatoprotective effect. Hepatoprotective agent-2 has antiapoptotic activity. Hepatoprotective agent-2 notably prevents the chemically induced elevation of hepatic indicators associated with liver injury .

HY-17464R

Cilostazol (Standard) OPC 13013 (Standard)	Reference Standards Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol (Standard) is the analytical standard of Cilostazol. This product is intended for research and analytical applications. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-42682R

D(+)-Galactosamine hydrochloride (Standard) D-Galactosamine HCl (Standard)	Reference Standards	Inflammation/Immunology
D(+)-Galactosamine (hydrochloride) (Standard) is the analytical standard of D(+)-Galactosamine (hydrochloride). This product is intended for research and analytical applications. D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-66005

Acetaminophen 60+ Cited Publications Paracetamol; 4-Acetamidophenol; 4'-Hydroxyacetanilide	COX Histone Acetyltransferase Endogenous Metabolite Bacterial Parasite Ferroptosis	Inflammation/Immunology Cancer
Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ of 25.8 μM; is a widely used antipyretic and analgesic agent. . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor . Acetaminophen induces ferroptosis and leads to acute liver injury in mice model .

HY-A0060

Malotilate NKK 105	Lipoxygenase	Cancer
Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC₅₀=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .

HY-125350

Entacapone acid Tyrphostin AG1290	c-Met/HGFR	Metabolic Disease
Entacapone acid (Tyrphostin AG1290) is a tyrosine kinase inhibitor. Entacapone acid reduces hepatic protein synthesis rate (HPS) in vivo .

HY-U00051

Propiomazine	Histamine Receptor	Neurological Disease
Propiomazine is an orally active antihistamine agent with sedative effects. Propiomazine can be used in the research of insomnia .

HY-U00051A

Propiomazine hydrochloride	Histamine Receptor
Propiomazine hydrochloride is an orally active antihistamine agent with sedative effects. Propiomazine hydrochloride can be used in the research of insomnia .

HY-P3148

Astin B	p62 Atg8/LC3 Apoptosis Autophagy Reactive Oxygen Species (ROS) JNK Bcl-2 Family Caspase	Metabolic Disease
Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression .

HY-167746

Nevirapine quinone methide	HIV	Infection
Nevirapine quinone methide is an active metabolite of Nevirapine, serving as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection and AIDS. Nevirapine quinone methide is associated with severe skin and liver injuries due to its metabolic activation pathways. Nevirapine quinone methide has been shown to inhibit CYP3A4, which could contribute to its hepatic toxicity.

HY-108467

GGsTop 5 Publications Verification Nahlsgen	γ-Glutamyl Transferase (GGT)	Cardiovascular Disease
GGsTop (Nahlsgen) is a potent, non-toxic, highly selective and irreversible γ-GGT inhibitor, with a K_i of 170 μM for Human GGT. GGsTop shows a pK_a of 9.71, also exhibits K_ons of 150 and 51 M ^-1 s ^-1 against E.coli GGT and human GGT, respectively. GGsTop protects hepatic ischemia-reperfusion injury in rat model .

HY-P10897

SjDX5-271	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Inflammation/Immunology
SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .

HY-A0060R

Malotilate (Standard)	Lipoxygenase	Cancer
Malotilate (Standard) is the analytical standard of Malotilate. This product is intended for research and analytical applications. Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .

HY-108467R

GGsTop (Standard)	γ-Glutamyl Transferase (GGT)	Cardiovascular Disease
GGsTop (Standard) is the analytical standard of GGsTop. This product is intended for research and analytical applications. GGsTop (Nahlsgen) is a potent, non-toxic, highly selective and irreversible γ-GGT inhibitor, with a Ki of 170 μM for Human GGT. GGsTop shows a pKa of 9.71, also exhibits Kons of 150 and 51 M-1 s-1 against E.coli GGT and human GGT, respectively. GGsTop protects hepatic ischemia-reperfusion injury in rat model .

HY-P10897A

SjDX5-271v	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Inflammation/Immunology
SjDX5-271v is a negative control of SjDX5-271 (HY-P10897). SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .

HY-148013

K284-6111	Glycosidase Amyloid-β NF-κB COX ERK NO Synthase Interleukin Related	Neurological Disease Inflammation/Immunology
K284-6111 is a high-affinity and orally active CHI3L1 inhibitor, and inhibits CHI3L1 expression. K284-6111 inhibits ERK and NF-κB pathway. K284-6111 suppresses nuclear translocation of p50 and p65, and phosphorylation of IκB. K284-6111 improves memory dysfunction by alleviating amyloidogenesis and neuroinflammation, with the reduction of inflammatory proteins (eg: iNOS, COX-2, GFAP, and Iba-1). K284-6111 reduces atopic-like skin inflammation and inhibits LPS (HY-D1056) -induced liver injury. K284-6111 can be used for the study of Alzheimer's diseases and sepsis like hepatic injury .

HY-P1624

Teduglutide 2 Publications Verification ALX-0600	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P1624A

Teduglutide TFA ALX-0600 TFA	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Thrombin COX ERK JNK Factor Xa	Cardiovascular Disease Inflammation/Immunology
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-121246

Fluorofenidone 1 Publications Verification AKF-PD	NF-κB ERK TGF-beta/Smad	Inflammation/Immunology Cancer
Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .

HY-121246R

Fluorofenidone (Standard)	Reference Standards NF-κB ERK TGF-beta/Smad	Inflammation/Immunology
Fluorofenidone (Standard) is the analytical standard of Fluorofenidone (AKF-PD) (HY-121246). This product is intended for research and analytical applications. Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .

HY-121246S

Fluorofenidone-d3 AKF-PD-d₃	Isotope-Labeled Compounds NF-κB ERK TGF-beta/Smad	Inflammation/Immunology Cancer
Fluorofenidone-d₃ (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .

HY-19696B

Tauroursodeoxycholate dihydrate Maximum Cited Publications 87 Publications Verification Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .

HY-117281S1

Moexipril-d3	Apoptosis Angiotensin-converting Enzyme (ACE) Isotope-Labeled Compounds	Cardiovascular Disease Neurological Disease
Moexipril-d₃ is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects ^- .

HY-117281

Moexipril	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease Neurological Disease
Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects ^- .

HY-B0378A

Moexipril hydrochloride RS-10085	Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease
Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects ^- .

HY-B0378AR

Moexipril hydrochloride (Standard) RS-10085 (Standard)	Reference Standards Angiotensin-converting Enzyme (ACE) Apoptosis	Cardiovascular Disease
Moexipril (hydrochloride) (Standard) is the analytical standard of Moexipril (hydrochloride). This product is intended for research and analytical applications. Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects - .

Cat. No.	Product Name

HY-L076

Drug-Induced Liver Injury (DILI) Compound Library	1,480 compounds
Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug. DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver. MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 1,480 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

Drug-Induced Liver Injury (DILI) Compound Library

1,480 compounds

Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.

DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.

MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 1,480 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.

Cat. No.	Product Name	Type

HY-P2149

Concanavalin A 5 Publications Verification	Native Proteins
Concanavalin A is a Ca ²⁺/Mn ²⁺-dependent and mannose/glucose-binding plant lectin that can be found in jack bean. Concanavalin A can induce programmed cell death. Concanavalin A can be used to induce acute hepatic injury .

Cat. No.	Product Name	Target	Research Area

HY-P10102

Kp7-6 2 Publications Verification	Apoptosis	Metabolic Disease Cancer
Kp7-6, a Fas mimetic peptide, is a Fas/FasL antagonist. Kp7-6 protects cells from Fas-mediated apoptosis, and protects mice from Fas-mediated hepatic injury .

HY-P10897

SjDX5-271	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Inflammation/Immunology
SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .

HY-P1624

Teduglutide 2 Publications Verification ALX-0600	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

HY-P3148

Astin B	p62 Atg8/LC3 Apoptosis Autophagy Reactive Oxygen Species (ROS) JNK Bcl-2 Family Caspase	Metabolic Disease
Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression .

HY-P10897A

SjDX5-271v	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Inflammation/Immunology
SjDX5-271v is a negative control of SjDX5-271 (HY-P10897). SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .

HY-P1624A

Teduglutide TFA ALX-0600 TFA	Nuclear Hormone Receptor 4A/NR4A FXR	Inflammation/Immunology
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2109

Macranthoidin A	Triterpenes Caprifoliaceae Classification of Application Fields Terpenoids Source classification Metabolic Disease Plants Disease Research Fields	Others
Macranthoidin A is an orally active saponin from Flos Lonicerae. Macranthoidin A possess protection effects on hepatic injury caused by Acetaminophen, Cd, and CCl4, and conspicuous depressant effects on swelling of ear croton oil .

HY-42682

D(+)-Galactosamine hydrochloride 2 Publications Verification D-Galactosamine HCl	Microorganisms Source classification Vitis vinifera cv. Zalema Plants Vitaceae Inflammation/Immunology Disease Research Fields Saccharides	Drug Derivative
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-N7905

Myricetin 3'-glucoside	Flavonoids Flavones Source classification Myrtaceae Syzygium malaccense (L.) Merr. et Perry Plants	Others
Myricetin 3'-glucoside is a glycoside derivative of quercetin. Myricetin 3'-glucoside significantly prevents ethanol-induced hepatotoxicity by reducing hepatic transaminase activity and inflammatory response in HepG2 cells. Myricetin 3'-glucoside has a certain protective effect on alcohol-induced liver injury .

HY-42682R

D(+)-Galactosamine hydrochloride (Standard) D-Galactosamine HCl (Standard)	Microorganisms Source classification Vitis vinifera cv. Zalema Plants Vitaceae Saccharides	Reference Standards
D(+)-Galactosamine (hydrochloride) (Standard) is the analytical standard of D(+)-Galactosamine (hydrochloride). This product is intended for research and analytical applications. D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-66005

Acetaminophen 60+ Cited Publications Paracetamol; 4-Acetamidophenol; 4'-Hydroxyacetanilide	Alkaloids Monophenols Classification of Application Fields Other Alkaloids Source classification Phenols Endogenous metabolite Inflammation/Immunology Disease Research Fields	COX Histone Acetyltransferase Endogenous Metabolite Bacterial Parasite Ferroptosis
Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ of 25.8 μM; is a widely used antipyretic and analgesic agent. . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor . Acetaminophen induces ferroptosis and leads to acute liver injury in mice model .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Cardiovascular Disease Flavonols Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Source classification Phenols Polyphenols Plants Disease Research Fields	Thrombin COX ERK JNK Factor Xa
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-19696B

Tauroursodeoxycholate dihydrate Maximum Cited Publications 87 Publications Verification Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .

HY-N2109R

Macranthoidin A (Standard)	Triterpenes Caprifoliaceae Terpenoids Source classification Plants	Reference Standards Others
Macranthoidin A (Standard) is the analytical standard of Macranthoidin A. This product is intended for research and analytical applications. Macranthoidin A is an orally active saponin from Flos Lonicerae. Macranthoidin A possess protection effects on hepatic injury caused by Acetaminophen, Cd, and CCl4, and conspicuous depressant effects on swelling of ear croton oil .

HY-P3148

Astin B	Alkaloids Other Alkaloids Source classification Plants Compositae Erythrina latissima E. Mey.	p62 Atg8/LC3 Apoptosis Autophagy Reactive Oxygen Species (ROS) JNK Bcl-2 Family Caspase
Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression .

Cat. No.	Product Name	Chemical Structure

HY-121246S

Fluorofenidone-d3

Fluorofenidone-d₃ (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .

HY-117281S1

Moexipril-d3
Moexipril-d₃ is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects ^- .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

hepatic injury

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products